Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the bodyâs own machinery â the T-cell â to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patientâs own T-cells to express our SPEAR TCRs to target and potentially destroy tumors. Source
No articles found.
Dyadic International, Inc. is a global biotechnology company based in Jupiter, Flo...
Dyadic International, Inc. is a global biotechn...
Infinity Pharmaceuticals, Inc. is an innovative biopharmaceutical company dedicate...
Infinity Pharmaceuticals, Inc. is an innovative...
Heska Corporation (NASDAQ: HSKA â News) manufactures, develops and sells advance...
Heska Corporation (NASDAQ: HSKA â News) manuf...
Nymox Pharmaceutical Corporation specializes in the research and development of th...
Nymox Pharmaceutical Corporation specializes in...
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company targeting the ...
Salarius Pharmaceuticals, Inc. is a clinical-st...
Neurotrope is a clinical-stage biotech company leveraging Bryostatin-1 and its ana...
Neurotrope is a clinical-stage biotech company ...
HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new...
HOOKIPA Pharma Inc. is a clinical stage biophar...
Join the National Investor Network and get the latest information with your interests in mind.